je.st
news
Tag: novartis
Premarket Biotech Digest: Valeant's M&A Prospects, Stocks Tumble, Novartis Promacta Extension
2015-08-25 23:15:17| Biotech - Topix.net
The iShares NASDAQ Biotechnology Index ETF fell another 4% on Monday and is now down more than 11% in the last three trading sessions amid a selloff in the broader market. Not surprisingly, the question every biotech focused investor is asking right now is whether this is an opportunity to buy.
Tags: extension
stocks
prospects
digest
Novartis buys remaining rights to GSK treatment in deal up to $1 billion
2015-08-21 09:12:45| Biotech - Topix.net
Swiss drugmaker Novartis said on Friday it had agreed to buy all remaining rights to Ofatumumab, which is being developed for relapsing remitting multiple sclerosis and other autoimmune indications, from Britain's GlaxoSmithKline. Basel-based Novartis will make an initial upfront payment of $300 million to GSK for the acquisition of the compound and a further $200 million payable following the start of a phase III study in MS by Novartis.
Tags: to
rights
treatment
deal
GSK sees drop in earnings after asset swap with Novartis
2015-07-29 15:23:08| Biotech - Topix.net
Britain-based drugmaker GlaxoSmithKline has reported a drop in earnings in the first full quarter since its deal to swap some assets with Swiss rival Novartis. Second-quarter net income fell to 149 million pounds from 654 million pounds a year earlier.
Premarket Biotech Digest: Novartis Earnings, Portola Lawsuits, Celgene's Orphan Drug
2015-07-23 11:13:42| Biotech - Topix.net
Xarelto, Eliquis and other anticoagulants that face products liability lawsuits have made deals with Portola, which is developing an antidote. One of the first anticoagulants, warfarin, was used as rat poison for 50 years before it began life as a blood thinner - and the only reason it did that was because a US Army sergeant who tried to kill himself with it was cured when treated with Vitamin K. Moral of the story- if you want to develop an anticoagulant, you better also develop its antidote, or you could bungle your way into multiple lawsuits.
Tags: drug
earnings
digest
biotech
Court ruling clears way for Novartis' low-cost biotech drug
2015-07-21 22:41:33| Biotech - Topix.net
A federal appeals court has ruled that Novartis can begin selling its lower-cost copy of an Amgen Inc. drug in September, rejecting a bid to further delay the launch of the knock-off biotech medication. Novartis received federal approval in March to sell its cheaper copy of Amgen's Neupogen, which is used to boost blood cells in cancer patients.
Tags: court
drug
ruling
biotech
Sites : [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] next »